133. Clin Breast Cancer. 2018 Mar 15. pii: S1526-8209(17)30455-X. doi:10.1016/j.clbc.2018.03.003. [Epub ahead of print]Breast Cancer and Ovulation Induction Treatments.Taheripanah R(1), Balash F(1), Anbiaee R(2), Mahmoodi M(3), Akbari Sene A(4).Author information: (1)Infertility and Reproductive Health Research Center, IVF Department, ShohadaTajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.(2)Oncology Department, Radio-oncology, Imam Hossein Hospital, Shahid BeheshtiUniversity of Medical Sciences, Tehran, Iran.(3)General Department, Shahriar Hospital, Tehran, Iran.(4)Shahid Akbar-Abadi Hospital IVF Center, IVF Department, Iran University ofMedical Sciences, Tehran, Iran. Electronic address: doctor_asturias@yahoo.com.BACKGROUND: This study was performed to determine whether the use of ovulationinduction drugs in treatment of infertility have a significant effect on the riskof breast cancer.PATIENTS AND METHODS: This case control study (928 cases, 928 controls), wasperformed in the gynecology and oncology clinics of Shahid Beheshti University ofMedical Sciences between 2011 and 2013. Data were collected via in-personinterviews using a questionnaire, which included demographic and gynecologicinformation. Statistical analysis was performed using SPSS statistics softwareversion 20 (IBM Corp).RESULTS: The use of ovulation induction drugs was not significantly associatedwith an increased risk of breast cancer (odds ratio [OR], 1.13; 95% confidenceinterval [CI], 0.7-1.855) among women with infertility (OR, 1.28; 95% CI,0.8-1.95).CONCLUSION: We observed no statistically significant relationship betweeninfertility and ovulation induction drugs with the risk of breast cancer, except for significant increases in the risk of breast cancer among patients who hadused fertility drugs for >6 months.Copyright Â© 2018 Elsevier Inc. All rights reserved.DOI: 10.1016/j.clbc.2018.03.003 PMID: 29628340 